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Adiponectin and Cardiovascular Disease
Response to Therapeutic Interventions
Seung Hwan Han, MD, PHD,* Michael J. Quon, MD, PHD,† Jeong-a Kim, PHD,†
Kwang Kon Koh, MD, PHD, FACC*
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Adiponectin is a protein secreted specifically by adipose cells that may couple regulation of insulin sensitivity
with energy metabolism and serve to link obesity with insulin resistance. Obesity-related disorders including the
metabolic syndrome, diabetes, atherosclerosis, hypertension, and coronary artery disease are associated with
decreased plasma levels of adiponectin, insulin resistance, and endothelial dysfunction. Adiponectin has insulin-
sensitizing effects as well as antiatherogenic properties. Lifestyle modifications and some drug therapies to treat
atherosclerosis, hypertension, and coronary heart disease have important effects to simultaneously increase adi-
ponectin levels, decrease insulin resistance, and improve endothelial dysfunction. In this review, we discuss in-
sights into the relationships between adiponectin levels, insulin resistance, and endothelial dysfunction that are
derived from various therapeutic interventions. The effects of lifestyle modifications and cardiovascular drugs on
adiponectin levels and insulin resistance suggest plausible mechanisms that may be important for treating ath-
erosclerosis and coronary heart disease. (J Am Coll Cardiol 2007;49:531–8) © 2007 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.061a
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clevated levels of free fatty acids associated with insulin
esistance, obesity, diabetes, and the metabolic syndrome
ause endothelial dysfunction by activating innate immune
nflammatory pathways upstream of nuclear transcription
actor kappa B (NF-B). Thus, inflammation contributes to
ndothelial dysfunction (1,2). The resultant decrease in
itric oxide (NO) bioactivity is important in the initiation,
rogression, and clinical expression of atherosclerosis. Insu-
in resistance (1), systemic hypertension, and hypercholes-
erolemia (2) all contribute independently to endothelial
ysfunction accompanied by inflammation in the vessel
all, which promotes development of atherosclerosis and
oronary heart disease.
Endothelial dysfunction is characterized by impaired NO
elease from endothelium and decreased blood flow to
nsulin target tissues (3). This results in impaired delivery of
ubstrate and hormone to skeletal muscle, which contributes
o insulin resistance. The pathogenic relationships among
besity, the metabolic syndrome, and its cardiovascular
omplications are well established. However, mechanisms
y which excess adiposity causes both insulin resistance and
ascular dysfunction are not well understood. Increasing
ttention has been paid to the direct vascular effects of
lasma proteins that originate from adipose tissue, especially
rom the *Division of Cardiology, Gil Heart Center, Gachon Medical School,
ncheon, Korea; and †Diabetes Unit, Laboratory of Clinical Investigation, NCCAM,
IH, Bethesda, Maryland.U
Manuscript received June 29, 2006; revised manuscript received August 17, 2006,
ccepted August 21, 2006.diponectin. Decreased plasma adiponectin levels are ob-
erved in patients with diabetes, metabolic syndrome, and
oronary artery disease (4,5), and this may play a key role in
he development of insulin resistance. Although the mech-
nisms underlying anti-inflammatory properties of adi-
onectin are not well understood (6), adiponectin’s anti-
nflammatory and antiatherogenic properties may be related,
n part, to its ability to stimulate production of NO from
ascular endothelium (7).
In this review, we discuss the antiatherogenic effects of
diponectin and its properties to improve and mimic met-
bolic and vascular actions of insulin. Particular emphasis is
iven to insights derived from therapeutic interventions
ith diet, exercise, cardiovascular drugs, insulin sensitizers,
nd combination therapies that simultaneously raise adi-
onectin levels and improve insulin sensitivity and endothe-
ial function.
iology, Regulation, and
etabolism of Adiponectin
he adipocyte is an active endocrine secretory cell releasing
ree fatty acids and producing several cytokines including
umor necrosis factor (TNF)-, interleukins (ILs), leptin,
nd adiponectin (6). Adiponectin is the most abundant
dipokine secreted by adipose cells that may couple regula-
ion of insulin sensitivity with energy metabolism. Adi-
onectin is a 30-kDa protein that consists of an N-terminal
ollagenous domain and a C-terminal globular domain.
nder normal conditions, the adiponectin gene (AMP1)
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expressed exclusively in adipose
tissue, and recent genome-wide
scans have mapped a diabetes sus-
ceptibility locus to this chromo-
some (8). The concentration of
adiponectin circulating in plasma
is very high (2 to 20 g/ml) (9).
Plasma levels of adiponectin in
the Japanese population is about
5 to 10 g/ml (10), and serum
adiponectin is lower in Indo-
Asians when compared with
Caucasians (median 3.3 vs. 4.9
g/ml) (11). Women have about
40% higher circulating levels of
adiponectin than men (9).
Adiponectin exists in the cir-
culation as a full-length protein
and a putative proteolytic cleav-
ge fragment consisting of the globular C-terminal domain.
his globular domain of adiponectin is pharmacologically
ctive and can regulate body weight and fatty acid oxidation
n mice (12). Adiponectin is found in multiple oligomeric
orms in serum, as a trimer and a hexamer (2 trimers) of
ower molecular weight (LMW) form: LMW isoform and
igh molecular weight (HMW) forms: HMW isoform (13).
he HMW form constitutes the major part of intracellular
diponectin, whereas the LMW form is predominant in the
irculation. Levels of HMW isoform have better correla-
ions with glucose tolerance than total adiponectin, suggest-
ng that the HMW isoform of adiponectin is the active form
14). The LMW and HMW isoforms of adiponectin
ctivate NF-B (15). The HMW isoform of adiponectin is
uppressed in coronary artery disease patients, and it is
levated on weight loss, and it suppresses human umbilical
ein endothelial cell apoptosis (16).
Two adiponectin receptor forms have been cloned. Adi-
oR1 is a high-affinity receptor for the globular C-terminal
omain of adiponectin with very low affinity for full-length
dioponectin. AdipoR1 is abundantly expressed in skeletal
uscle whereas AdipoR2 is most abundant in the liver
here it has intermediate affinity for both forms of adi-
onectin (17). Overexpression or knock-down of Adi-
oR1/R2 suggests that these receptors mediate increased
denosine monophosphate (AMP) kinase and peroxisome
roliferator-activated receptor (PPAR) ligands activities, as
ell as fatty-acid oxidation and glucose uptake by
dioponectin (17). Adiponectin receptors are expressed in
ancreatic -cells (18), macrophages, and atherosclerotic
esions (19). Adiponectin receptor expression is increased by
eta-cell exposure to the unsaturated free fatty acid oleate,
nd treatment of insulin-producing cells with globular
diponectin induces lipoprotein lipase expression (18).
Adiponectin itself is controlled in conditions of metabolic
Abbreviations
and Acronyms
AMP  adenosine
monophosphate
CRP  C-reactive protein
HMW  high molecular
weight
IL  interleukin
LMW  low molecular
weight
NF-B  nuclear
transcription factor
kappa B
NO  nitric oxide
PPAR  peroxisome
proliferator-activated
receptor
TNF  tumor necrosis
factortress and by a number of hormones and factors involved in aegulation of metabolic function. Insulin lowers adiponectin
xpression in both mice and humans (20). Thiazolidinedi-
nes, as potent PPAR agonists, increase the expression of
diponectin (20,21). Most other factors with a significant
mpact on adiponectin regulation have inhibitory effects.
hese include catecholamines, glucocorticoids, cytokines
IL-6 and TNF-), prolactin, growth hormone, and
ndrogens (22).
ntiatherogenic Effects of Adiponectin
aboratory data. ADIPONECTIN AND ENDOTHELIAL CELLS.
diponectin reduces expression of adhesion molecules in
ndothelial cells and decreases cytokine production from
acrophages by inhibiting NF-B signaling through
AMP-dependent pathway (Fig. 1, Table 1) (23,24). At
hysiological levels, adiponectin exhibits specific and satu-
able binding to aortic endothelial cells and readily binds to
he walls of catheter-injured vessels more than to intact
ascular walls (25). Endothelium-dependent vasodilation in
esponse to acetylcholine is significantly reduced in
diponectin-knockout mice when compared with wild-type
ice (26).
DIPONECTIN AND MONOCYTE-MACROPHAGES, FOAM
ELL TRANSFORMATION. Adiponectin suppresses macro-
hage to foam cell transformation and prevents vascular
tenosis. Adiponectin induces production of anti-
nflammatory mediators IL-10 and -1 receptor antagonist
27). Expression of the scavenger receptor class A-1 of
acrophages is inhibited by adiponectin, resulting in mark-
dly decreased uptake of oxidized low-density lipoprotein
nd inhibition of foam cell formation (25). Adiponectin has
nhibitory effects on the proliferation of myelomonocytic
ineage cells and on the function of matured macrophages
28). Interleukin-6 treatment inhibits adiponectin gene
xpression and secretion in 3T3-L1 adipocytes (29). Adi-
onectin and TNF- mutually inhibit each other’s produc-
ion in adipose tissue, and physiological concentrations of
diponectin inhibit TNF-–induced monocyte adhesion to
uman aortic endothelial cells, as well as the expression of
arious adhesion molecules (Fig. 1) (23). In addition,
diponectin selectively increases tissue inhibitor of
etalloproteinase-1 expression in human monocyte-derived
acrophages through IL-10 induction (30).
DIPONECTIN AND SMOOTH MUSCLE CELLS. Adiponectin
uppresses the proliferation and migration of smooth muscle
ells induced by platelet-derived growth factor in smooth
uscle cells (31). Increasing adiponectin levels using an
denoviral vector attenuates neointimal proliferation in
echanically balloon injured arteries in adiponectin-
eficient mice (32).
DIPONECTIN AND INFLAMMATORY MARKERS. Plasma C-
eactive protein (CRP) levels are negatively correlated with
lasma adiponectin levels in male patients with coronary
rtery disease, and CRP messenger ribonucleic acid is
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nverse correlation is observed between CRP and adiponectin
essenger ribonucleic acid levels in human adipose tissues
33). Recent studies report an inverse correlation between
lasma adiponectin and IL-6 concentrations (34). Thus, adi-
onectin may indirectly inhibit CRP and IL-6 expression
hrough its ability to inhibit production of TNF-.
esults from clinical surveys. Decreased plasma adi-
onectin levels are observed in patients with obesity, type 2
iabetes, hypertension, metabolic syndrome, and coronary
rtery disease (4,5,23,35,36). Low plasma adiponectin levels
re significantly correlated with endothelial dysfunction
26). These results suggest that low adiponectin levels may
e a useful marker for early-stage atherosclerosis. Hypoadi-
onectinemia correlates significantly and independently
ith coronary artery disease (4). Plasma concentrations of
diponectin in patients with acute coronary syndrome are
ignificantly lower than those in patients with stable angina
nd in the control group (37). In addition, low plasma
diponectin levels are associated with progression of coro-
ary artery calcification in type 1 diabetic and non-diabetic
ubjects independently of other cardiovascular risk factors
38). Plasma adiponectin levels are an inverse predictor of
ardiovascular outcome in patients with end-stage renal
isease and stroke (39–41).
esults from population surveys. Adiponectin levels in
ale subjects were measured at baseline and then followed
or 6 years. Individuals with adiponectin concentrations in
Figure 1 Antiatherogenic Effects of Adiponectin
Adiponectin has novel vascular actions to directly stimulate production of nitric oxi
ways involving phosphorylation of endothelial nitric oxide synthase (eNOS) by aden
adhesion molecules and decreases cytokine production from macrophage by inhib
monophosphate-dependent pathways (23,24). Modified from Koh KK, Han SH, Qu
interventions. J Am Coll Cardiol 2005;46:1978–85. IB  inhibitory kappa B.he highest quintile compared with the lowest quintile have pdecreased risk for myocardial infarction (42). In addition,
diponectin is associated with a decreased risk for coronary
eart disease events in same cohort, men with diabetes (43).
owever, adiponectin did not predict coronary heart disease
vents in women (44). Therefore, additional prospective
tudies are required to determine whether there is a true
ender difference in the effect of adiponectin on coronary
eart disease.
ffects of Adiponectin to Mimic and
ugment Metabolic Actions of Insulin
aboratory data. Activation of AMP kinase by adi-
onectin leads to expression of PPAR and induces
ncreased gene expression of enzymes of fatty acid oxi-
ation and glucose uptake (45). Adiponectin decreases
epatic glucose production by inhibiting enzymes of
luconeogenesis, and thus contributes to reduction in
lood glucose levels in normal and diabetic animals (46).
f interest, administration of adiponectin improves in-
ulin sensitivity in adiponectin-deficient mice made in-
ulin resistant on a high-fat diet (47). Insulin, glucocor-
icoids, thyroid hormones, and growth hormone impair
lucose tolerance, and/or contribute to insulin resistance.
mong these hormones, only insulin and glucocorticoids
uppress expression of adiponectin in adipocytes (48).
A number of genetic studies have demonstrated clear
ssociations of polymorphisms and resulting in hypoadi-
) in endothelial cells using phosphatidylinositol (PI) 3-kinase-dependent path-
monophosphate-activated protein kinase (AMPK) (7) and reduces expression of
uclear transcription factor kappa B (NF-B) signaling through cyclic adenosine-
 Inflammatory markers and the metabolic syndrome: insights from therapeuticde (NO
osine-
iting n
on MJ.onectinemia with insulin resistance, diabetes, and cardio-
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Adiponectin and Cardiovascular Diseases February 6, 2007:531–8ascular disease (8,49). These genetic factors may be rele-
ant to effects of treatment with PPAR agonists (50).
vidence from clinical studies. Low adiponectin levels are
ssociated with the metabolic syndrome and development of
ype 2 diabetes (5,51). Serum concentrations of adiponectin
orrelated strongly with insulin sensitivity in human (52).
ubjects with type 2 diabetes have lower plasma concentra-
ions of adiponectin than matched non-diabetic control
ubjects (36).
ffects of Therapeutic Interventions
ifestyle modifications. Prolonged weight loss restores
diponectin levels (36) (Table 2). The HMW isoform of
diponectin is significantly increased, and levels of trimer
nd hexamer decline during weight loss (16).
Combined hypocaloric diet and moderate physical activ-
ty induce significant weight loss and increase of plasma
diponectin especially among diabetic subjects (53). After 2
ears of weight loss and lifestyle changes, adiponectin levels
ntiatherogenic and Anti-Insulin–Resistantroperties of Adiponectin and I hibitors ofdi onectin Expressio
Table 1
Antiatherogenic and Anti-Insulin–Resistant
Properties of Adiponectin and Inhibitors of
Adiponectin Expression
Antiatherogenic Properties of Adiponectin References
Stimulates production of NO 7
Suppresses human umbilical vein endothelial cells apoptosis 16
Reduces expression of adhesion molecules in endothelial cells 23
Decreases cytokine production from macrophages 24
Improves endothelium-dependent vasodilation 26
Induces production of IL-10 and -1 receptor antagonists 27
Suppresses macrophage-to-foam cell transformation 25
Inhibits expression of scavenger receptor class A-1 of
macrophages
25
Inhibits proliferation of myelomonocytes and function of
mature macrophages
28
Increases tissue inhibitor of metalloproteinase-1 expression in
human monocyte-derived macrophages
30
Suppresses proliferation and migration of smooth muscle cells 31
Suppresses expression of growth factor in endothelial cells 32
Anti-Insulin–Resistant Properties of Adiponectin
Ameliorates insulin resistance and increases
fatty acid oxidation
12,45,47
Decreases hepatic glucose production by inhibiting enzymes
of gluconeogenesis
46
Inhibitors of Adiponectin Expression
TNF- inhibits adiponectin production in adipose tissue 23
IL-6 inhibits adiponectin gene expression and secretion in
3T3-L1 adipocytes
29
CRP inhibits adiponectin mRNA levels in human adipose tissues 33
Insulin suppresess gene expression of adiponectin in adipocytes 20,48
Glucocorticoids suppress gene expression of adiponectin
in adipocytes
48
Beta-adrenergic agonists inhibit gene expression of adiponectin 56
Hydrogen peroxide and nicotine reduce expression and
secretion of adiponectin
56
RP C-reactive protein; IL interleukin; mRNAmessenger ribonucleic acid; NO nitric oxide;
NF  tumor necrosis factor.ncrease significantly (54). Plasma levels of adiponectin are Pegatively associated with smoking status in patients with
oronary artery disease (55). Increasing activity of the
ympathetic nervous system, which is affected by nicotine,
lso decreases plasma levels of adiponectin. Moreover,
-adrenergic agonists and cyclic AMP analogues inhibit the
ene expression of adiponectin (56). Consistent with this,
diponectin levels are significantly lower in current smokers
han in non-smokers. In cultured mouse 3T3-L1 adipo-
ytes, hydrogen peroxide and nicotine reduce messenger
ibonucleic acid expression and secretion of adiponectin in a
ose-dependent manner (57).
ardiovascular drugs. RENIN-ANGIOTENSIN SYSTEM
LOCKING AGENTS. Renin-angiotensin system blocking
gents significantly increase adiponectin levels with accom-
anying improvement in insulin sensitivity without affecting
he degree of adiposity (58). Losartan alone or combined
herapy with simvastatin and losartan in hypercholester-
lemic, hypertensive patients significantly increases plasma
diponectin levels and insulin sensitivity relative to baseline
easurements, but simvastatin alone therapy does not (59).
amipril alone or combined therapy with simvastatin and
amipril in patients with type 2 diabetes shows the same
herapeutic Interventionsn R ising Adipon c in Levels
Table 2 Therapeutic Interventionson Raising Adiponectin Levels
Lifestyle Modifications References
Weight loss restores adiponectin levels 16,36
Combined diet control and physical exercise increases
plasma levels of adiponectin
53,54
Smoking habit decreases plasma adiponectin concentration 55,57
Increasing activity of the sympathetic nervous system
decreases plasma levels of adiponectin
56
Renin-Angiotensin System Blocking Agents
Temocapril and ramipril increase adiponectin levels 60
Losartan and candesartan increase adiponectin levels 58,59,63,67
PPAR Agonists
PPAR agonist induces AdipoR2 on human
primary macrophage
19
Fenofibrate increases adiponectin levels 19,65,67,68
PPAR Agonists
Thiazolidinediones induces expression and secretion of
adiponectin in humans and rodents in vivo and in vitro
21
Thiazolidinediones increase adiponectin levels in diabetic,
lean control, and obese control subjects
69
Hypoglycemic Drugs
Glimepiride increases plasma adiponcetin levels in elderly
patients with type 2 diabetes
70
Metformin does not alter plasma adiponectin levels in
obese patients with type 2 diabetes
71
Statins
Simvastatin, atorvastatin, and rosuvastatin do not change
plasma levels of adiponectin
59,68,77
New Beta-Blockers
Nebivolol increases plasma adiponcetin levels in
hypertensive patients
79PAR  peroxisome proliferator-activated receptor.
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February 6, 2007:531–8 Adiponectin and Cardiovascular Diseasesesults (60). Potential mechanisms for renin angiotensin
ystem blocking agents to affect adiponectin levels include
irect effects on glucose insulin-stimulated glucose uptake,
romotion of adipogenic differentiation of preadipocytes
61), and/or induction of PPAR activity promoting differ-
ntiation in adipocytes (62). Recent clinical trials demon-
trate that renin-angiotensin system blockades lower the
isk of development of type 2 diabetes. One of the mecha-
isms underlying this effect may be an increase in adiponec-
in levels and insulin sensitivity (63).
PAR AGONISTS. The PPAR activators improve insulin
ensitivity and reduce adiposity in rodent models (64).
dipoR2 is induced by both PPAR and PPAR (19).
enofibrate therapy significantly increases plasma adiponec-
in levels and insulin sensitivity in primary hypertriglyceri-
emic patients (65). Significant correlations between the
egree of changes in adiponectin levels and insulin levels,
RP levels, and insulin sensitivity (assessed by Quantitative
nsulin-Sensitivity Check Index [QUICKI]) were observed
fter fenofibrate therapy. Fenofibrate therapy for 2 months
reatment increases adiponectin levels without a change in
ody weight. This raises the possibility that drug therapy is
irectly altering adiponectin levels independent of adiposity
66). We also investigated the effects of fenofibrate, cande-
artan, and combined therapy in hypertriglyceridemic, hy-
ertensive patients. Fenofibrate, combined therapy, and
andesartan significantly increased plasma adiponectin lev-
ls and insulin sensitivity relative to baseline measurements
67). In another study, fenofibrate alone or combined
herapy with atorvastatin and fenofibrate for 2 months in
atients with combined hyperlipidemia significantly in-
reased plasma adiponectin levels and insulin sensitivity
elative to baseline measurements, but atorvastatin alone
herapy does not (68).
PAR AGONISTS. Thiazolidinediones induce expression and
ecretion of adiponectin in humans and rodents in vivo and
n vitro without affecting body weight (21). Adiponectine
evels rise uniformly in diabetic, lean control and obese
ontrol subjects after thiazolidinedione treatment (69).
limepiride not only improves insulin resistance but also
ncreases plasma adiponectin levels in elderly patients with
ype 2 diabetes (70). By contrast, metformin does not alter
lasma adiponectin levels or adiponectin content in abdom-
nal adipocytes even though glycemic control is similar in
oth troglitazone and metformin groups in obese patients
ith type 2 diabetes (71).
TATINS, BETA-BLOCKERS, AND DIURETICS. The effects of
tatins on insulin sensitivity are controversial. Simvastatin
nd atorvastatin improve insulin sensitivity in diabetic
atients (72); however, others have reported that simvasta-
in either did not change or worsened insulin sensitivity in
iabetic patients (73,74). Indeed, recent large-scale clinical
tudies have demonstrated that statins, particularly high
ose, may increase, not decrease, the onset of new diabetes75,76). Simvastatin, atorvastatin, or rosuvastatin does not
hange plasma levels of adiponectin and insulin sensitivity
59,68,77). Old beta-blockers and diuretics seem to have
egative effects on insulin sensitivity (78). Nevertheless, new
eta-blockers increase plasma adiponectin levels and im-
rove insulin sensitivity (79).
uture Prospects
diponectin is a target for future research in reducing
orbidity and mortality of atherosclerotic disease. Diet,
xercise, cardiovascular drugs, and insulin sensitizers im-
rove endothelium-dependent vascular function, increase
diponectin levels, and reduce inflammation and insulin
esistance by distinct mechanisms (Fig. 2). This may help
xplain beneficial effects of combination therapies in recent
linical trials. Thus, there is a scientific rationale for recom-
ending a combination of lifestyle modifications and mul-
iple drugs from separate classes to prevent atherosclerosis
nd coronary heart disease. Recent evidence suggests that
ross-talk between inflammatory signaling pathways and
nsulin signaling pathways causes both metabolic insulin
esistance and endothelial dysfunction that synergize to
redispose to cardiovascular disorders in the metabolic
yndrome (Fig. 3) (3,80). Prospective studies are needed to
xamine the ability of increases in adiponectin levels and
nsulin sensitivity to improve primary end points including
ncidence of diabetes and outcomes of cardiovascular events.
t is possible that recombinant adiponectin may have a
eneficial therapeutic role in the treatment and prevention
f cardiovascular diseases in the future.
Figure 2 Mechanisms of Therapeutic Interventions on Adi-
ponectin, Insulin Resistance, and Endothelial Function
Lifestyle modifications and cardiovascular drugs such as fenofibrate, angioten-
sin-converting enzyme inhibitors (ACEIs), angiotensin II type I receptor blockers
(ARBs), and thiazolidinediones (TZDs) increase plasma levels of adiponectin,
reduce insulin resistance, and improve endothelial function. These may be one
mechanism to reduce cardiovascular diseases by these therapeutic interven-
tions used in recent clinical trials.
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